Conference Day 1

All agenda times are in EST. For PST, download the full event guide here.

8:30 am Registration & Coffee

Elucidating the Trial Landscape of Multi-Functional Cell Therapies with the First In- Human Data

9:15 am Chair’s Opening Remarks

9:30 am Sharing an Overview of Key Developments & Players in the Multi-Functional Cell Therapy Space


  • Providing a comprehensive overview of the pipeline of multi-functional cell therapies for solid tumors
  • Analyzing the available clinical data to inform future development
  • Sharing insights into the different targeted approaches, current trends and future directions

10:00 am The Evolution of Clinical Development for TIL Cell Therapy in Solid Tumors


  • Delivering broader access to TIL through multi-center studies and scalable manufacturing
  • Clinical Data for TIL in metastatic melanoma, metastatic non-small cell lung and advanced cervical cancers
  • Clinical data for TIL in combination with other therapies in earlier cancer treatment settings
  • Research on genetically-modified TIL as a next-generation approach

10:30 am Morning Break & Speed Networking

Overcoming Toxicity, Resistance & Durability by Understanding TME & Biological Activity of Cell Therapies

11:30 am Overcoming the Barriers to Treating Solid Tumors by Employing Multiple Mechanisms of Action to Target Tumor Cells & the TME


  • Understanding the role of distinct immune cell types in attacking solid tumors
  • Harnessing the complementary mechanisms of action of T cells to deliver a multifaceted attack on the tumor leading durable long-term
  • Considering patient selection and biomarker strategy to predict clinical benefit

12:00 pm Lunch & Networking

Adding Functions for Improved Targeting

1:30 pm Using Logic Gated Gene Circuits to Create “Smarter” Cell Therapies


  • Logic Gating: Introduction and Therapeutic Application
  • NOT Logic Gated CAR-NK cell therapies for increased specificity and safety
  • OR/NOT Logic Gated CAR-NK cell therapies for increased efficacy and safety, as well as reduced tumor antigen escape

2:00 pm A Cell Therapy that Targets Gene Loss with a Logic-Gate to Differentiate Between Normal and Tumor Cells


  • The problem: Targeting cell therapies to solid tumors
  • The solution: Engineering a dual signal-integration mechanism (Tmod) that exploits loss of heterozygosity to distinguish between normal and tumor cells
  • The evidence: in vitro and in vivo studies with CEA and MSLN to support safety and efficacy for a Tmod logicgated cell therapy
  • The platform can be readily extended to other antigens

Exploiting Different Cell Types

1:30 pm Panel Discussion: Leveraging Different Cell Types to Create More Controllable Cell Therapies


  • Identifying the characteristics of the more traditional and emerging cell types used in cell therapy and discussing their pros and cons
  • Mapping out how novel engineering approaches can help combine the therapeutic effect of each cell type
  • Sharing effective assays and cell processing procedures to quantify therapeutic impact

2:00 pm CRISPR/Cas9 Engineered TIL for Enhanced Anti-Tumor Function

  • Karrie Wong Director of Cell Therapy, KSQ Therapeutics


  • CRISPRomics® screens for identification of target and target combinations to enhance T cell anti-tumor function
  • Application of top targets for generation of eTILTM therapy

2:30 pm Allocetra: Off-The-Shelf, Universal, Macrophage Reprogramming Cell Therapies For Life-Threatening Diseases Including Solid Tumors


  • Introducing  Allocetra – a new modality of macrophages reprogramming into their homeostatic state for treatment of unmet medical conditions
  • Presenting significant synergistic anti-cancer combination therapy effect of Allocetra and CAR-T in human cervical cancer mice model
  • Discussing the transition into first in human clinical studies in peritoneal metastasis

2:40 pm Afternoon Break & Networking

3:30 pm Realizing Effective Homing Strategies to Deliver Cell Therapies to Tumor Sites


  • Deploying and enhancing the innate and adaptive immune systems to prolong the response
  • Enhancing intratumoral trafficking through a combination of targeting and engineering approaches to localize to the tumor microenvironment

4:00 pm Towards the Development of Multiplexed Cellular Therapies: The Promise of iPSC Derived T-cell Products

  • Chris Bond Senior Vice President Pre-Clinical & Translational Sciences, Notch Therapeutics


  • Design of effective allogeneic cell therapies requires multiplexed engineering.
  • Clinical success in solid tumor settings will require multiple mechanisms of action.
  • Stem Cell derived products enable identification and expansion of engineered products without deleterious off target damage.
  • Control of Notch signaling is critical for lineage commitment and differentiation potential of developing T-cells

4:30 pm Improving Specificity by Expanding the Repertoire of Targets by Utilizing Both Intra- & Extra- Cellular Targets


  • Highlighting advantages of intracellular targets (pHLAs) versus conventional cell surface antigens
  • Providing strategies to find the most prevalent and immunogenic targets in tumors of CPI responders
  • Selecting pHLA targets with highest tumor vs normal ratios to avoid off-tumor target toxicities

3:30 pm Utilizing the Superior Antibody-Dependent Cellular Cytotoxicity, Effector Functions, & Improved Persistence of g-NK Cells When Compared to Conventional NK Cells

  • Austin Bigley Vice President of Research & Development, Indapta


  • Discussing the enhanced in vivo efficacy and persistence of g-NK cells and the ability of g-NK cells to induce regression of established tumors leading to durable elimination of tumor burden
  • Elucidating the unique feature of g-NK cells which enable the development of an off-the-shelf cancer immunotherapy combined with therapeutic IgG
  • Combining g-NK cells with anti-CD38 antibodies for the treatment of multiple myeloma without the need for genetic engineering

4:00 pm Harnessing the Unique Features of Macrophage Therapies with CAR Technology (CAR-M) to Fight Solid Tumors

  • Thomas Condamine Senior Director, Discovery & Translational Sciences, Carisma Therapeutics


  • Maintaining the anti-tumoral polarization within the TME and selective targeting of cancer cells by direct killing activity
  • Phagocytosis of tumor target leads to cross-presentation of tumor antigen and activation of an adaptive immune response
  • Presenting initial data from CT-0508 phase I clinical study, studying the impact of Her2-directed CAR-M in solid tumor

4:30 pm Leveraging Tumor-Infiltrating B Cells to Enhance Melanoma TIL

  • Daniel Abate-Daga Associate Professor, H. Lee Moffitt Cancer Center and Research Institute & University of South Florida


  • The complex and uncharacterized nature of the TME and TIL populations
  • Sharing a protocol to expand TIL from frozen tumor digests that involves activation of melanoma-infiltrating B cells
  • Describing the Effects on TIL phenotype and expansion of the CD4 compartment

5:00 pm Chair’s Closing Remarks & End of Day 1